DEVICE CATEGORY · PLS
Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1
The programmed death-ligand 1 (PD-L1) antibody is a qualitative immunohistochemical antibody intended to identify PD-L1 protein expression in human clinical tissue specimens. The PD-L1 antibody is indicated as an aid in identifying patients eligible for treatment with specific FDA approved therapeutic drugs or to assess PD-L1 expression level in patients who may respond particularly well to specific FDA approved therapeutic drugs.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 22C3 pharmDxP150013/S034 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S035 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
PD-L1 IHC 28-8 pharmDxP150025/S018 | Agilent Technologies, Inc. | PMA supplement | Jul 1, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S031 | Agilent Technologies, Inc. | PMA supplement | Mar 19, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S032 | Agilent Technologies, Inc. | PMA supplement | Feb 11, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S033 | Agilent Technologies, Inc. | PMA supplement | Feb 10, 2026 | FDA |
PD-L1 IHC 22C3 pharmDx (Dako Omnis)P150013/S028 | Agilent Technologies, Inc. | PMA supplement | Aug 4, 2025 | FDA |
PD-L1 IHC 22C3 PHARMDXP150013 | Agilent Technologies, Inc. | PMA approval | Oct 2, 2015 | FDA |
Source information
Follow the FDA links to view the original records.




